Literature DB >> 4414543

Magnesium oxide-pyridoxine therapy for recurrent calcium oxalate calculi.

E L Prien, S F Gershoff.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4414543     DOI: 10.1016/s0022-5347(17)59777-3

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


× No keyword cloud information.
  8 in total

1.  Effect of blind treatment on stone disease.

Authors:  Y M Fazil Marickar; Abiya Salim; Adarsh Vijay
Journal:  Urol Res       Date:  2009-12-08

2.  Urine composition in patients with urolithiasis during treatment with magnesium oxide.

Authors:  H G Tiselius; C Ahlstrand; L Larsson
Journal:  Urol Res       Date:  1980

3.  Bioavailability of magnesium from different pharmaceutical formulations.

Authors:  Roswitha Siener; Andrea Jahnen; Albrecht Hesse
Journal:  Urol Res       Date:  2010-09-23

4.  A contribution to the formation mechanism of calcium oxalate urinary calculi. III. On the role of magnesium in the formation of oxalate calculi.

Authors:  W Berg; A Hesse; H J Schneider
Journal:  Urol Res       Date:  1976

5.  Magnesium deficiency in children with urolithiasis.

Authors:  V Revúsová; J Gratzlová; V Zvara; J Krídl
Journal:  Int Urol Nephrol       Date:  1976       Impact factor: 2.370

6.  Effect of combined supplementation of magnesium oxide and pyridoxine in calcium-oxalate stone formers.

Authors:  V Rattan; H Sidhu; S Vaidyanathan; S K Thind; R Nath
Journal:  Urol Res       Date:  1994

7.  Control of hyperoxaluria with large doses of pyridoxine in patients with kidney stones.

Authors:  A Mitwalli; A Ayiomamitis; L Grass; D G Oreopoulos
Journal:  Int Urol Nephrol       Date:  1988       Impact factor: 2.370

8.  Kidney stones.

Authors:  C R Kleeman; J W Coburn; A S Brickman; D B Lee; R G Narins; R M Ehrlich
Journal:  West J Med       Date:  1980-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.